

TRISTEL plc
("Tristel" or the "Company")

Result of AGM

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

Resolution 1, which sought to receive and adopt the Company's annual accounts for the financial year ended 30 June 2025, together with the Directors' report, the Directors' remuneration report and the auditor's report on those accounts, passed with 59% of votes cast. With respect to this resolution the Company received notice from one of the proxy voting advisers that they were recommending investors to vote against it, due to lack of a separate vote for remuneration policy and the level of loss of office payment to a former Director accompanied by limited disclosure.

Resolution 1 has been discussed with several of the institutional shareholders and within the Board. The Board undertakes that it will ensure any necessary future disclosure complies with best practice, along with committing to put the remuneration policy to a separate vote at future AGMs, in line with QCA guidance.

The Company would like to reiterate that it takes its shareholder responsibilities seriously and has a clear focus on striving for governance best practice, sharpening capital allocation and driving sustainable growth.

The results of the AGM will be made available on the Company's website: <https://tristelgroup.com/invest/annual-general-meeting-agm/>

For further information please contact:

Tristel plc

Matt Sassone, Chief Executive Officer
Anna Wasyl, Chief Financial Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd

Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500



About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFLFELFVLLIE